<DOC>
	<DOCNO>NCT01076270</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy total-body irradiation ( TBI ) donor peripheral blood stem cell transplant help stop growth cancer cell help stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Giving colony-stimulating factor , filgrastim ( G-CSF ) plerixafor , donor help stem cell move ( mobilization ) bone marrow blood collect store . PURPOSE : This clinical trial study give plerixafor filgrastim together mobilization donor peripheral blood stem cell peripheral blood stem cell transplant treat patient hematologic malignancy</brief_summary>
	<brief_title>Plerixafor Filgrastim For Mobilization Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant Treating Patients With Hematologic Malignancies</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . The percentage normal donor collect least 2 x 10^6 CD34 cells/kg recipient weight day 1 administration combine filgrastim plerixafor . SECONDARY OBJECTIVES : I . Measuring CD34+ cells/ul peripheral blood donor 11 , 15 , 24 36 hour post dose . II . Tolerance safety combine filgrastim Plerixafor normal donor . III . Engraftment filgrastim/plerixafor mobilized stem cell allogeneic recipient . IV . Acute chronic graft-versus-host disease ( GVHD ) follow use filgrastim/plerixafor mobilized stem cell . V. Yield CD34+ cell base donor weight . OUTLINE : Donors receive filgrastim subcutaneously ( SC ) plerixafor SC day -14 undergo leukapheresis collect peripheral blood stem cell ( PBSC ) day -13 . These cell freeze preserve . Treatment modification may apply accord sufficient collection PBSC . Patients receive standard high-dose conditioning undergo allogeneic PBSC transplantation day 0 use previously frozen cell . After completion study treatment , donor follow 1 day last stem cell donation .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic , Atypical , BCR-ABL Negative</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Hematologic malignancy consider eligible suitable allogeneic stem cell transplantation ( syngeneic transplantation acceptable ) ; diagnose include acute myeloid lymphoid leukemia , chronic myeloid lymphoid leukemia , multiple myeloma , lymphoma myelodysplasia ; subject suitable study primarily receive transplant standard treatment plan ( non research regimen ) Organ function , performance status age suitable ablative regimen consist TBI &gt; = 10Gy chemotherapy regimen consist busulphan cyclophosphamide ( BuCY ) busulphan melphalan ( BuMel ) Availability fully match sibling donor Ability understand willingness sign inform consent No uncontrolled infection DONOR : Human leukocyte antigen ( HLA ) identical sibling donor DONOR : &gt; = 18 year DONOR : No unacceptable risk donor due preexist illness DONOR : Must suitable antecubital vein leukapheresis venipuncture ; donor require temporary , Mahurkartype catheter eligible DONOR : Ability willingness sign inform consent document Eligible willingness participate research study transplant regimens Eligible willingness participate non ablative transplant regimen Human immunodeficiency virus ( HIV ) seropositive Pregnancy DONOR : HIV seropositive DONOR : Contraindication hypersensitivity filgrastim plerixafor DONOR : Hepatitis A , B , C seropositive DONOR : Pregnant lactating female DONOR : Liver function study &gt; 2 time upper limit normal ( ULN ) evaluation , Creatinine &gt; 2 , pulmonary function diffuse lung capacity carbon monoxide ( DLCO ) &lt; 50 % ( specifically evaluate ) , cardiac ejection fraction &lt; 50 % ( specifically evaluate ) DONOR : Any known ventricular arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>